Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

2033 ARTÍCULOS , VIENDO DEL 1411 AL 1425

White Matter Hyperintensity as a Vascular Contribution to the AT(N) Framework

Ng KP, Shen JY, Chiew HJ, Ng ASL, Kandiah N, Rosa-Neto P, Gauthier S.

J Prev Alzheimers Dis. 2023;10(3):387-400. doi: 10.14283/jpad.2023.53.

Charting the Next Road Map for CSF Biomarkers in Alzheimer's Disease and Related Dementias

Hu WT, Nayyar A, Kaluzova M.

Neurotherapeutics. 2023 Jul;20(4):955-974. doi: 10.1007/s13311-023-01370-8. Epub 2023 Jun 28.

Predicting cognitive decline in older people by structural and molecular imaging

Teipel S, Tang Y, Boccardi M.

Curr Opin Neurol. 2023 Aug 1;36(4):253-263. doi: 10.1097/WCO.0000000000001172. Epub 2023 Jun 19.

MRI in the new era of antiamyloid mAbs for the treatment of Alzheimer's disease

Filippi M, Cecchetti G, Agosta F.

Curr Opin Neurol. 2023 Aug 1;36(4):239-244. doi: 10.1097/WCO.0000000000001177. Epub 2023 Jun 23.

Clinical trials in dementia with Lewy bodies: the evolving concept of co-pathologies, patient selection and biomarkers

Gibson LL, Abdelnour C, Chong J, Ballard C, Aarsland D.

Curr Opin Neurol. 2023 Aug 1;36(4):264-275. doi: 10.1097/WCO.0000000000001173. Epub 2023 Jun 9.

A review of neuroimaging-based data-driven approach for Alzheimer's disease heterogeneity analysis

Liu L, Sun S, Kang W, Wu S, Lin L.

Rev Neurosci. 2023 Jul 10;35(2):121-139. doi: 10.1515/revneuro-2023-0033. Print 2024 Feb 26.

Efficacy and safety of anti-amyloid-β monoclonal antibodies in current Alzheimer's disease phase III clinical trials: A systematic review and interactive web app-based meta-analysis

Jeremic D, Navarro-López JD, Jiménez-Díaz L.

Ageing Res Rev. 2023 Sep;90:102012. doi: 10.1016/j.arr.2023.102012. Epub 2023 Jul 7.

The hidden players: Shedding light on the significance of post-translational modifications and miRNAs in Alzheimer's disease development

Singh R, Hussain J, Kaur A, Jamdare BG, Pathak D, Garg K, Kaur R, Shankar S, Sunkaria A.

Ageing Res Rev. 2023 Sep;90:102002. doi: 10.1016/j.arr.2023.102002. Epub 2023 Jul 7.

The Synergistic Potential of Combining PD-1/PD-L1 Immune Checkpoint Inhibitors with NOD2 Agonists in Alzheimer's Disease Treatment

Ghareghani M, Rivest S.

Int J Mol Sci. 2023 Jun 30;24(13):10905. doi: 10.3390/ijms241310905.

Biomarker disclosure protocols in prodromal Alzheimer's disease clinical trials

Rahman-Filipiak A, Bolton C, Grill JD, Rostamzadeh A, Chin N, Heidebrink J, Getz S, Fowler NR, Rosen A, Lingler J, Wijsman E, Clark L; Advisory Group on Risk Evidence Education in Dementia (AGREED).

Alzheimers Dement. 2023 Sep;19(9):4270-4275. doi: 10.1002/alz.13380. Epub 2023 Jul 14.

PET Radiomics of White Matter, Can Be Employed as a Biomarker to Identify the Progression of Mild Cognitive Impairment to Alzheimer's Disease

Chen F.

Acad Radiol. 2023 Sep;30(9):1885-1886. doi: 10.1016/j.acra.2023.06.020. Epub 2023 Jul 17.

Biomarkers in Alzheimer Disease: A Review

Karceski S, Antonopoulos M.

Neurology. 2023 Jul 25;101(4):e461-e463. doi: 10.1212/WNL.0000000000207630.

Impact of sharing Alzheimer's disease biomarkers with individuals without dementia: A systematic review and meta-analysis of empirical data

van der Schaar J, Visser LNC, Ket JCF, Groot C, Pijnenburg YAL, Scheltens P, Bredenoord AL, van den Hoven MA, van der Flier WM.

Alzheimers Dement. 2023 Dec;19(12):5773-5794. doi: 10.1002/alz.13410. Epub 2023 Jul 26.

Blood-based biomarkers for Alzheimer's disease: a multicenter-based cross-sectional and longitudinal study in China

Gao F, Dai L, Wang Q, Liu C, Deng K, Cheng Z, Lv X, Wu Y, Zhang Z, Tao Q, Yuan J, Li S, Wang Y, Su Y, Cheng X, Ni J, Wu Z, Zhang S, Shi J, Shen Y; China Aging and Neurodegenerative Initiative (CANDI) Consortium.

Sci Bull (Beijing). 2023 Aug 30;68(16):1800-1808. doi: 10.1016/j.scib.2023.07.009. Epub 2023 Jul 10.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias